Tri-salt form of metformin
Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.
1. A composition comprising a salt of metformin, an amino acid, and a polyunsaturated fatty acid, the salt having the structure of Formula II
wherein R − is a polyunsaturated fatty acid, and n is 1 or 2, and an anti-hyperlipidemic agent, an anti-hyperglycemic agent, or both.
2. The composition of claim 1 , wherein R − is eicosapentaenoate or docosahexaenoate.
3. The composition of claim 1 , wherein R − is eicosapentaenoate or docosahexaenoate, and n is 1.
4. The composition of claim 1 , wherein R − is eicosapentaenoate or docosahexaenoate, and n is 2.
5. The composition of claim 1 further comprising a pharmaceutically acceptable carrier, vehicle or diluent.
6. The composition of claim 1 , wherein the anti-hyperlipidemic agent is selected from a statin, an HMG CoA enzyme inhibitor, a cholesterol absorption inhibitor, or a cholesterol esterase transfer protein (CETP) inhibitor.
7. The composition of claim 6 , wherein the anti-hyperlipidemic agent is a statin.
8. The composition of claim 7 , wherein the statin is selected from the group consisting of atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, rosuvastatin, cerivastatin, mevastatin, rivastatin, pitavastatin, nisvastatin, itavastatin, velostatin and fluindostatin, pharmaceutically-acceptable salts or prodrugs thereof, and pharmaceutically-acceptable salts of said prodrugs.
9. The composition of claim 8 , wherein the statin is selected from atorvastatin, rosuvostatin, simvastatin, or pravastatin.
10. The composition of claim 1 , wherein the anti-hyperglycemic agent is selected from the group consisting of sulfonylureas, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, DPP IV inhibitors, SGLT-2 inhibitors and pharmaceutically-acceptable salts and prodrug thereof, and pharmaceutically-acceptable salts of said prodrug.
11. The composition of claim 10 , wherein the anti-hyperglycemic agent is a DPP IV inhibitor or an SGLT-2 inhibitor.
12. The composition of claim 11 , wherein the DPP IV inhibitor is selected from the group consisting of sitagliptin, linagliptin, vildagliptin, saxagliptin, alogliptin, denagliptin, carmegliptin, melogliptin, dutogliptin and pharmaceutically-acceptable salts and prodrugs thereof, and pharmaceutically-acceptable salts of said prodrugs.
13. The composition of claim 11 , wherein the SGLT-2 inhibitor is selected from the group consisting of dapagliflozin canagliflozin, atigliflozin, remogliflozin, sergliflozin, and pharmaceutically-acceptable salts and prodrugs thereof, and pharmaceutically-acceptable salts of said prodrugs.
14. The composition of claim 1 , wherein the composition comprises an anti-hyperlipidemic agent.
15. The composition of claim 14 , wherein R − is eicosapentaenoate or docosahexaenoate.
16. The composition of claim 14 , wherein R − is eicosapentaenoate or docosahexaenoate, and n is 1.
17. The composition of claim 14 , wherein R − is eicosapentaenoate or docosahexaenoate, and n is 2.
18. The composition of claim 1 , wherein the composition comprises an anti-hyperglycemic agent.
19. The composition of claim 18 , wherein R − is eicosapentaenoate or docosahexaenoate.
20. The composition of claim 18 , wherein R − is eicosapentaenoate or docosahexaenoate, and n is 1.
21. The composition of claim 18 , wherein R − is eicosapentaenoate or docosahexaenoate, and n is 2.
22. A kit comprising a) a unit dosage form comprising the composition of claim 1 , b) instructions on how to use the kit; and c) at least one container for holding the unit dosage form.
23. A method for treating diabetes or lowering triglycerides in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 1 .
24. The method of claim 23 , further comprising administering metformin (free base), or a salt form of metformin.
25. The method of claim 24 , wherein the salt form of metformin is metformin docosahexaenoate, metformin eicosapentaenoate, metformin hydrochloride, metformin succinate, or metformin fumarate.
26. The method of claim 23 , wherein the subject is a mammal.
27. The method of claim 23 , wherein the subject is a human.
28. The method of claim 23 , wherein the composition comprises an anti-hyperglycemic agent selected from the group consisting of sulfonylureas, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, DPP IV inhibitors, SGLT-2 inhibitors and pharmaceutically-acceptable salts and prodrug thereof, and pharmaceutically-acceptable salts of said prodrug.
29. The method of claim 28 , wherein the anti-hyperglycemic agent is a DPP IV inhibitor or an SGLT-2 inhibitor.
30. The method of claim 29 , wherein the DPP IV inhibitor is selected from the group consisting of sitagliptin, linagliptin, vildagliptin, saxagliptin, alogliptin, denagliptin, carmegliptin, melogliptin, dutogliptin and pharmaceutically-acceptable salts and prodrugs thereof, and pharmaceutically-acceptable salts of said prodrugs.
31. The method of claim 30 , wherein the SGLT-2 inhibitor is selected from the group consisting of dapagliflozin canagliflozin, atigliflozin, remogliflozin, sergliflozin, and pharmaceutically-acceptable salts and prodrugs thereof, and pharmaceutically-acceptable salts of said prodrugs.
32. A method for treating cardiovascular disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 14 .
33. The method of claim 32 , wherein the cardiovascular disease is selected from the group consisting of cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke.
34. The method of claim 33 , wherein the cardiovascular disease is myocardial infarction or stroke.
35. The method of claim 32 , wherein the subject is mammal.
36. The method of claim 34 , wherein subject is human.
37. The method of claim 32 , wherein the anti-hyperlipidemic agent is selected from a statin, an HMG CoA enzyme inhibitor, a cholesterol absorption inhibitor, or a cholesterol esterase transfer protein (CETP) inhibitor.
38. The method of claim 37 , wherein the anti-hyperlipidemic agent is a statin.
39. The method of claim 38 , wherein the statin is selected from the group consisting of atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, rosuvastatin, cerivastatin, mevastatin, rivastatin, pitavastatin, nisvastatin, itavastatin, velostatin and fluindostatin, pharmaceutically-acceptable salts or prodrugs thereof, and pharmaceutically-acceptable salts of said prodrugs.
40. The method of claim 39 , wherein the statin is selected from atorvastatin, rosuvostatin, simvastatin, or pravastatin.